GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LIM:MRNA) » Definitions » Loans Receivable

Moderna (LIM:MRNA) Loans Receivable : $0 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Moderna Loans Receivable?

Moderna's Loans Receivable for the quarter that ended in Dec. 2023 was $0 Mil.


Moderna Loans Receivable Historical Data

The historical data trend for Moderna's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Loans Receivable Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial - - - - -

Moderna Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Moderna Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Moderna Loans Receivable Related Terms

Thank you for viewing the detailed overview of Moderna's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna (LIM:MRNA) Business Description

Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna (LIM:MRNA) Headlines

From GuruFocus

Moderna Inc at UBS BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc ASCO Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc R&D Day Transcript

By GuruFocus Research 01-23-2024

Moderna Inc Vaccines Day Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc to Host ESG Day Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024